Cell Based Assay & High Content Screening Markets. Forecasts by User and Product. With Executive and Consultant Guides. 2024 to 2028

Cell Based Assays are a mainstay of drug development and scientific research, and now, post pandemic, research activity is rebounding. On top of this new technology is allowing Cell Based Assays to be used to measure any aspect of cell function. This market just keeps on growing with no end in sight. The workhorse of the pharmaceutical industry is becoming a central player in biotechnology.

This is a complex area but this readable report will bring the entire management team up to speed, on both the technology and the opportunity.

The technology is moving faster than the market. Genomics and Immunology are playing a role too. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

B.Sc. (Chemistry) University of BC
M.B.A. (Finance and Policy) University of BC
Market Research Seminar - Burke Institute
Finance for Senior Executives - Harvard Business School

1. Market Guides

1.1. Situation Analysis
1.2. Guide for Executives and Marketing Staff
1.3. Guide for Investment Analysts and Management Consultants

2. Introduction and Market Definition

2.1. What are Cell Based Assays?
2.2. Clinical Trial Failures
- 2.2.1. Immuno-oncology Plays a Leading Role in Cell Based Assays
2.3. Infectious Disease Will Play a Larger Role
2.4. Market Definition
- 2.4.1. Market Size
- 2.4.2. Currency
- 2.4.3. Years
2.5. Methodology
- 2.5.1. Methodology
- 2.5.2. Sources
- 2.5.3. Authors
2.6. U.S. Medical Market and Pharmceutical Research Spending -
Perspective
- 1.5.1. U.S. Expenditures for Pharmaceutical Research

3. Cell Based Assays-Guide to Technology

3.1. Cell Cultures
- 3.1.1. Cell Lines
- 3.1.2. Primary Cells
- 3.1.3. Stem Cells
- 3.1.4. iPSC's-The Special Case
3.2. Cell Assays
3.3. Cell Viability Assays
3.4. Cell Proliferation Assays
3.5. Cytotoxicity Assays
3.6. Cell Senescence Assays
3.7. Apoptosis
3.8. Autophagy
3.9. Necrosis
3.10. Oxidative Stress
3.11. 2D vs. 3D
3.12. Signalling Pathways, GPCR
3.13. Immune Regulation & Inhibition
3.14. Reporter Gene Technology
3.15. CBA Design & Development
3.16. Cell Based Assays-The Takeaway

4. Industry Overview

4.1. Players in a Dynamic Market
- 4.1.1. Academic Research Lab
- 4.1.2. Contract Research Organization
- 4.1.3. Genomic Instrumentation Supplier
- 4.1.4. Cell Separation and Viewing Supplier
- 4.1.5. Cell Line and Reagent Supplier
- 4.1.6. Pharmaceutical Company
- 4.1.7. Audit Body
- 4.1.8. Certification Body

5. Market Trends

5.1. Factors Driving Growth
- 5.1.1. Candidate Growth
- 5.1.2. Immuno-oncology
- 5.1.3. Genomic Blizzard
- 5.1.4. Technology Convergence
- 5.1.5. The Insurance Effect
5.2. Factors Limiting Growth
- 5.2.1. CBA Development Challenges
- 5.2.2. Instrument Integration
- 5.2.3. Protocols
5.3. Technology Development
- 5.3.1. 3D Assays
- 5.3.2. Automation
- 5.3.3. Software
- 5.3.4. Primary Cells
- 5.3.5. Signalling and Reporter Genes
- 5.3.6. The Next Five Years

6. Cell Based Assays Recent Developments

6.1. Recent Developments-Importance and How to Use This Section
- 6.1.1. Importance of These Developments
- 6.1.2. How to Use This Section
6.2. Castle Biosciences Sees Big Gains in New Testing Niches
6.3. Cell-Based Assay Outperforms Others
6.4. 3D spheroid model Monitors T-cell invasion
6.5. BioAuxilium Launches New Biomarker Assay
6.6. Charles River Laboratories Acquires SAMDI Tech
6.7. Axion BioSystems Launches New High-Throughput Live-Cell Imaging Platform
6.8. Fujifilm's Life Sciences Invests in PhenoVista Biosciences
6.9. Nucleai Launches New Multiplex Imaging Spatial Analysis Solution
6.10. BIO-TECHNE ANNOUNCES MULTI-OMIC RNASCOPE ASSAYS
6.11. Indivumed, CellPhenomics Partner on Cancer Drug Target Research
6.12. Synthego to Accelerate Drug Discovery
6.13. Long COVID Detected By Cell-Based Assay
6.14. Nanolive closes a USD 20 million Funding Round
6.15. Depixus Seeks to Commercialize 'Magnetic Tweezers' for Drug Discovery
6.16. BioAuxilium Research Expands its Cell Signaling Assay Portfolio
6.17. Droplet Genomics Debuts New Microfluidic Screening Platform
6.18. DLP Plus Single-Cell Sequencing Method Spreads From Canada to Cancer Labs Worldwide
6.19. Secondcell Bio to Make Creation of Cell Lines Easy
6.20. Nanolitre-scale cell assays developed with droplet microarraymass spec
6.21. Thermo Fisher Scientific Acquires Cell Sorting Technology
6.22. Cellink to Distribute Phasefocus High-Content Cell Imaging Platform
6.23. Axxam and FUJIFILM Cellular Dynamics Announce Strategic Alliance
6.24. Cancer Genetics to Acquire Organoid Startup Stemonix
6.25. Curi Bio Acquires Artificial Intelligence Firm Dana Solutions
6.26. CRISPR Screens Uncover Novel Cancer Therapy Targets
6.27. ERS Genomics Licenses CRISPR-Cas9 Patents to Axxam

7. Profiles of Key Cell Based Assay Companies

7.1. Abcam
7.2. Agilent
7.3. Aurora Biomed
7.4. Axxam
7.5. Beckman Coulter Diagnostics
7.6. Becton, Dickinson and Company
7.7. Berkley Lights
7.8. BioIVT
7.9. Bio-Rad Laboratories, Inc.
7.10. BMG Labtech
7.11. Bruker
7.12. Cell Biolabs, Inc.
7.13. Cell Signaling Technology, Inc.
7.14. Charles River Laboratories
7.15. Corning, Inc.
7.16. Cytek Biosciences
7.17. Cytovale
7.18. Deepcell
7.19. Enzo Biochem
7.20. Eurofins DiscoverX Corporation
7.21. Evotec AG
7.22. Excellerate Bioscience
7.23. Fujifilm Cellular Dynamics International
7.24. Genedata
7.25. Hemogenix
7.26. Invivogen
7.27. Leica Biosystems
7.28. Lonza Group Ltd.
7.29. Luminex Corp (DiaSorin)
7.30. Merck & Co., Inc
7.31. Miltenyi Biotec
7.32. Molecular Devices
7.33. Nanion
7.34. Ncardia
7.35. New England Biolabs, Inc.
7.36. Novogene Bioinformatics Technology Co., Ltd.
7.37. Olympus
7.38. Origene Technologies
7.39. Promega
7.40. Qiagen
7.41. Reaction Biology
7.42. Recursion Pharma
7.43. Revvity
7.44. Roche Diagnostics
7.45. Sartorius
7.46. Sartorius-ForteBio
7.47. Sartorius-IntelliCyt
7.48. Singleron Biotechnologies
7.49. Sony Biotechnology
7.50. SPT Labtech
7.51. Stemcells Technologies Canada Inc.
7.52. Tecan
7.53. Thermo Fisher Scientific Inc.
7.54. Vitro Biopharma

8. Global Market Size

8.1. Global Market Overview by Country
- 8.1.1. Table-Global Market by Country
- 8.1.2. Chart - Global Market by Country
8.2. Global Market by User - Overview
- 8.2.1. Table-Global Market by User
- 8.2.2. Chart-Global Market by User-Base/End Year Comparison
- 8.2.3. Chart-Global Market by User-Base Year
- 8.2.4. Chart-Global Market by User-End Year
- 8.2.5. Chart-Global Market by User-Share by Year
8.3. Global Market by Product Class - Overview
- 8.3.1. Table-Global Market by Product Class
- 8.3.2. Chart-Global Market by Product Class-Base/End Year Comparison
- 8.3.3. Chart-Global Market by Product Class-Base Year
- 8.3.4. Chart-Global Market by Product Class-End Year
- 8.3.5. Chart-Global Market by Product Class-Share by Year

9. Global Market by User Type

9.1. Pharma
- 9.1.1. Table Pharma-by Country
- 9.1.2. Chart - Pharma Growth
9.2. Research
- 9.2.1. Table Research-by Country
- 9.2.2. Chart - Research Growth
9.3. Industry/Cosmetic
- 9.3.1. Table Industry/Cosmetic-by Country
- 9.3.2. Chart - Industry/Cosmetic Growth

10. Cell Based Assay by Product Class

10.1. Instrument
- 10.1.1. Table Instrument-by Country
- 10.1.2. Chart - Instrument Growth
10.2. Reagent
- 10.2.1. Table Reagent-by Country
- 10.2.2. Chart - Reagent Growth
10.3. Services
- 10.3.1. Table Services-by Country
- 10.3.2. Chart - Services Growth
10.4. Software
- 10.4.1. Table Software-by Country
- 10.4.2. Chart - Software Growth

11. Appendices

11.1. FDA Cancer Drug Approvals by Year
11.2. Clinical Trials Started
11.3. Share of Pharma R&D by Country

Table of Tables

Table 1: The Large Variety of Cell Lines
Table 2: Some Common Viability Assays
Table 3: Oxidative Stress Related Diseases
Table 4: Important Signalling Pathways
Table 5: Market Players by Type
Table 6: Five Factors Driving Growth
Table 7: Three Factors Limiting Growth
Table 8: - Global Market by Region
Table 9: Global Market by User
Table 10: Global Market by Product Class
Table 11: Pharma by Country
Table 12: Research by Country
Table 13: Industry/Cosmetic by Country
Table 14: Instrument by Country
Table 15: Reagent by Country
Table 16: Services by Country
Table 17: Software by Country

Table of Figures

Figure 1: Reasons for clinical Failure by Phase
Figure 2: Immunotherapy Clinical Trial Growth
Figure 3: Pharmaceutical Research Expenditures ($Billion)
Figure 4: Oxidative Stress and Free Radical Toxicity
Figure 5: FDA Cancer Drug Approvals
Figure 6: The Changing Approach to Cancer Diagnostics
Figure 7: Growth rates of Cell Based Assays by Product Class
Figure 8: Global Market Share Chart
Figure 9: Global Market by User-Base vs. End Year
Figure 10: Global Market by User Base Year
Figure 11: Global Market by User End Year
Figure 12: User Share by Year
Figure 13: Global Market by Product Class-Base vs. End Year
Figure 14: Global Market by Product Class Base Year
Figure 15: Global Market by Product Class End Year
Figure 16: Product Class Share by Year
Figure 17: Pharma Growth
Figure 18: Research Growth
Figure 19: Industry/Cosmetic Growth
Figure 20: Instrument Growth
Figure 21: Reagent Growth
Figure 22: Services Growth
Figure 23: Software Growth
Figure 24: FDA Cancer Drug Approvals by Year
Figure 25: Clinical Trials for Immunotherapy by Year
Figure 26: Share of Pharma R&D by Country